Pharmaceutical & Biotech
De-risk the candidate before it reaches GLP toxicology
De-risk R&D and regulatory submission is the line that opens every dossier Biobide sends a sponsor, and on this model it means something concrete: at 5 days post-fertilization the zebrafish embryo already has a beating heart, a working liver and a nervous system responding to stimuli, on a genome that shares over 80% of its genes with ours. Our DART screening has been validated at 88% sensitivity and accuracy with mammalian concordance confirmed — signal a sponsor can act on while the molecule is still cheap to change.
Selected clients in this space: NIH · MMV · DNDi
Why sponsors route candidates through Biobide first
A whole organism, read out in days
Not a single-target readout
CARDIOTOX runs on a GFP-heart transgenic line with our own Cardio v3.0 software, catching fibrillation, bradycardia and AV-block — off-target cardiac signal a hERG assay in isolation won't surface.
Validated, not just internally consistent
The safety suite's DART screening carries an externally validated 88% sensitivity and accuracy, mammalian concordance confirmed — the kind of figure a regulator, or a licensing partner's due diligence team, will actually ask to see.
Inside the NAM Zone by design, not by exception
Every core assay runs within the animal welfare burden window defined by EU Directive 2024/1262 — up to 120 hpf — so a full systemic profile never crosses into animal-testing regulation. That is the 3Rs commitment in practice, not a slogan next to it.
Disease models built to the target, not off a shelf
CNS, oncology, cardiovascular and metabolic models — Duchenne, ALS, Dravet and tauopathy among them — sourced in-house or via MTA when target validation needs more than a wild-type embryo.
Relevant from the catalogue
Assays this industry books most
The panel below is what pharma and biotech sponsors actually book. Each card links to the full guideline breakdown.
Systemic & Developmental Toxicology
ACUTETOX, TERATOTOX, CARDIOTOX, HEPATOTOX, NEUROTOX, OTOTOX, IMMUNOTOX, NEPHROTOX
OECD 236-based · View assays →
Genotoxicity
Core in vitro battery plus in vivo follow-up
ICH S2(R1) · View assays →
Efficacy & Disease Models
Target validation, HCS phenotypic screening, custom disease models
View assays →
Endocrine Disruption Screening
EASZY & ZETA transgenic assays
OECD TG 250 · View assays →
Regulatory context
Data is generated to sit ahead of ICH-aligned non-clinical safety packages, with genotoxicity follow-up strategies built directly around the ICH S2(R1) weight-of-evidence framework.
Send us the series, not just the lead candidate
We scope a screening battery against your compound list and timeline, and assign a Study Director before the first plate is run.
